RESULTS	Post hoc analyses revealed a significantly lower risk of at least moderately severe persistent TD persisting for 1 month ( P = .012 ) and probable TD not persisting for 1 month ( Criterion A , P = .030 ; Criterion B , P = .048 ) in OLZ-treated patients .\